Header Logo

Connection

Michael Liptay to Neoplasm Staging

Back to Details
This is a "connection" page, showing publications Michael Liptay has written about Neoplasm Staging.
Michael Liptay
Connection Strength
1.645
Neoplasm Staging
  1. Current concepts in the staging of non-small cell lung cancer. Surg Oncol. 2002 Dec; 11(4):181-90.
    View in: PubMed
    Score: 0.197
  2. Redefining the Risk of Surgery for Clinical Stage IIIA (N2) Non-Small Cell Lung Cancer: A Pooled Analysis of the STS GTSD and ESTS Registry. Lung. 2021 06; 199(3):311-318.
    View in: PubMed
    Score: 0.177
  3. Improved False-Positive Rates and the Overestimation of Unintended Harm from Lung Cancer Screening. Lung. 2019 06; 197(3):327-332.
    View in: PubMed
    Score: 0.153
  4. Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer. Lung Cancer. 2011 Feb; 71(2):186-90.
    View in: PubMed
    Score: 0.083
  5. Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? Ann Thorac Surg. 2009 Sep; 88(3):937-43; discussion 944.
    View in: PubMed
    Score: 0.079
  6. Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. J Thorac Oncol. 2009 Mar; 4(3):338-47.
    View in: PubMed
    Score: 0.076
  7. Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. J Thorac Oncol. 2009 Feb; 4(2):198-202.
    View in: PubMed
    Score: 0.076
  8. Repeat pulmonary resection for metachronous colorectal carcinoma is beneficial. Surgery. 2008 Oct; 144(4):712-7; discussion 717-8.
    View in: PubMed
    Score: 0.073
  9. In vivo sentinel lymph node mapping in lung cancer. Ann Surg Oncol. 2005 Feb; 12(2):102-3.
    View in: PubMed
    Score: 0.057
  10. Sentinel lymph node mapping in lung cancer. Cancer Treat Res. 2005; 127:141-50.
    View in: PubMed
    Score: 0.057
  11. Intraoperative sentinel lymph node mapping in non-small-cell lung cancer improves detection of micrometastases. J Clin Oncol. 2002 Apr 15; 20(8):1984-8.
    View in: PubMed
    Score: 0.047
  12. Definition and assessment of high risk in patients considered for lobectomy for stage I non-small cell lung cancer: The American Association for Thoracic Surgery expert panel consensus document. J Thorac Cardiovasc Surg. 2021 12; 162(6):1605-1618.e6.
    View in: PubMed
    Score: 0.045
  13. Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters. Ann Thorac Surg. 2017 Nov; 104(5):1637-1643.
    View in: PubMed
    Score: 0.034
  14. Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer. J Thorac Cardiovasc Surg. 2016 Jul; 152(1):55-61.e1.
    View in: PubMed
    Score: 0.031
  15. Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response. J Thorac Oncol. 2015 Oct; 10(10):1475-80.
    View in: PubMed
    Score: 0.030
  16. Thoracoscopic staging and surgical therapy for esophageal cancer. Chest. 1995 Jun; 107(6 Suppl):218S-223S.
    View in: PubMed
    Score: 0.029
  17. Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):307-16.
    View in: PubMed
    Score: 0.029
  18. Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer. Lung Cancer. 2015 Jun; 88(3):267-74.
    View in: PubMed
    Score: 0.029
  19. Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2015 Mar; 149(3):727-34.e1-3; discussion 734.
    View in: PubMed
    Score: 0.028
  20. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base. Cancer. 2014 Jul 01; 120(13):2060-8.
    View in: PubMed
    Score: 0.027
  21. Prevalence and predictors of neoadjuvant therapy for stage IIIA non-small cell lung cancer in the National Cancer Database: importance of socioeconomic status and treating institution. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):303-12.
    View in: PubMed
    Score: 0.027
  22. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):370-5.
    View in: PubMed
    Score: 0.025
  23. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol. 2012 Dec; 21(4):207-13.
    View in: PubMed
    Score: 0.025
  24. Development of a serum biomarker panel predicting recurrence in stage I non-small cell lung cancer patients. J Thorac Cardiovasc Surg. 2012 Dec; 144(6):1344-50; discussion 1350-1.
    View in: PubMed
    Score: 0.024
  25. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun; 6(6):1079-86.
    View in: PubMed
    Score: 0.022
  26. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg. 2011 Jul; 92(1):233-41; discussion 241-3.
    View in: PubMed
    Score: 0.022
  27. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):985-91.
    View in: PubMed
    Score: 0.021
  28. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010 Apr 01; 126(7):1630-9.
    View in: PubMed
    Score: 0.020
  29. The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy. Ann Thorac Surg. 2009 Sep; 88(3):945-50; discussion 950-1.
    View in: PubMed
    Score: 0.020
  30. Endobronchial colorectal metastasis versus primary lung cancer: a tale of two sleeve right upper lobectomies. Interact Cardiovasc Thorac Surg. 2009 Aug; 9(2):379-81.
    View in: PubMed
    Score: 0.019
  31. Contemporary review on the inequities in the management of lung cancer among the African-American population. J Natl Med Assoc. 2008 Jun; 100(6):683-8.
    View in: PubMed
    Score: 0.018
  32. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer. Lung Cancer. 2004 Aug; 45(2):243-53.
    View in: PubMed
    Score: 0.014
  33. Critical factors for patient management. Lung Cancer. 2003 Dec; 42 Suppl 1:S7-8.
    View in: PubMed
    Score: 0.013
  34. Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1997 Apr; 113(4):691-8; discussion 698-700.
    View in: PubMed
    Score: 0.008
  35. An historical perspective of multi-modality treatment for resectable non-small cell lung cancer. Lung Cancer. 1995 Jun; 12 Suppl 2:S17-32.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.